Document Detail

Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass.
MedLine Citation:
PMID:  8231205     Owner:  NLM     Status:  MEDLINE    
Extensive contact between blood and artificial surfaces causes platelet activation and depletion. The aim of the study was to test the efficacy of Ro 44-9883, a new nonpeptide, reversible, glycoprotein IIb/IIIa antagonist in preventing platelet count drop in dogs undergoing cardiopulmonary bypass during 2 hours. Twenty-two heparinized dogs were divided into three groups, one control group (n = 9) not treated, one group treated with a low dose of Ro 44-9883 (145 micrograms/kg intravenously, n = 6), and one group treated with a high dose of Ro 44-9883 (870 micrograms/kg intravenously, n = 7). In the control group, platelet counts declined to 53% +/- 15% of initial levels at the start of cardiopulmonary bypass and remained lower than 80% of initial levels during follow-up. Platelet count drop was completely prevented in the Ro 44-9883 high-dose group, whereas it was only partially prevented in the low-dose group. Blood loss was similar in the three groups despite the fact that bleeding times were longer in the Ro 44-9883 high-dose group than in the control group. We conclude that Ro 44-9883, together with heparin as a standard anticoagulant, is highly effective in preventing platelet count drop during cardiopulmonary bypass without causing excessive bleeding.
J P Carteaux; S Roux; H Kuhn; T Tschopp; V Colombo; P Hadváry
Related Documents :
2006775 - Double-blind study of suppression of indoor fungi and bacteria by the puridyne biogenic...
19802625 - Effect of polymyxin b-immobilized fiber hemoperfusion on respiratory impairment, hepato...
19641715 - Association between mean platelet volume and autonomic nervous system functions: increa...
24615745 - Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
18753425 - Selenium status in patients with aspirin-induced asthma.
12526795 - A stimulatory role for cgmp-dependent protein kinase in platelet activation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  106     ISSN:  0022-5223     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1993-12-08     Completed Date:  1993-12-08     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  834-41     Citation Subset:  AIM; IM    
Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / pharmacology*
Blood Coagulation Tests
Blood Loss, Surgical / prevention & control
Cardiopulmonary Bypass / adverse effects*
Fibrinogen / analysis
Microscopy, Electron, Scanning
Oxygenators, Membrane
Platelet Aggregation / drug effects*
Platelet Count / drug effects
Platelet Membrane Glycoproteins / antagonists & inhibitors*
Tyrosine / analogs & derivatives*,  pharmacology
Reg. No./Substance:
0/Acetates; 0/Platelet Membrane Glycoproteins; 144412-49-7/lamifiban; 55520-40-6/Tyrosine; 9001-32-5/Fibrinogen
Comment In:
J Thorac Cardiovasc Surg. 1993 Nov;106(5):931-3   [PMID:  8231218 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Next Document:  New configuration of double cardiomyoplasty based on studies of the length-tension properties of the...